Navigation Links
Shionogi Inc. Announces Commercial Availability of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD
Date:1/10/2011

FLORHAM PARK, N.J., Jan. 10, 2011 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial availability for the non-central nervous system stimulant medication KAPVAY™, an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.  KAPVAY™ is the first and only FDA-approved ADHD treatment indicated for use as add-on therapy to stimulant medication, in addition to use as monotherapy.

"Shionogi is extremely proud to bring KAPVAY™ to market in the U.S.," said Donald C. Manning, MD, PhD, Chief Medical Officer of Shionogi Inc.  "The extended-release version of clonidine hydrochloride found in KAPVAY™ offers an exciting new treatment option for children and adolescents with ADHD who are not experiencing adequate symptom relief from stimulants alone."  

ADHD affects more than 4.5 million children in the U.S., with at least 7 percent of U.S. school-aged children believed to suffer from the condition.  Symptoms include difficulty in maintaining attention and focus and in controlling behavior, as well as hyperactivity/over-activity.  While stimulant medications remain a first line treatment for ADHD, up to 30 percent of ADHD patients do not achieve an optimal response to stimulant monotherapy.

KAPVAY™'s recent FDA approval was based on two Phase III studies, which demonstrated significant efficacy at Week 5 in children and adolescents (6-17 years) with ADHD treated with KAPVAY™.  Signs and symptoms of ADHD were evaluated using the investigator administered and scored ADHD Rating Scale-IV-Parent Version (ADHDRS-IV) total score, including hyperactive/impulsivity and inattentive subscales.  Treatment-emergent adverse events, such as somnolence and fatigue, were mostly mild to moderate. Thirteen percent (13%) of patients
'/>"/>

SOURCE Shionogi Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
2. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
3. BioCrysts Partner Shionogi Launches Peramivir In Japan Under The Name RAPIACTA
4. Shionogi Enters Into Exclusive License Agreement With QuatRx Pharmaceuticals To Market Ospemifene
5. Shionogi Inc. Announces FDA Approval of CUVPOSA™ for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions
6. Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... YORK , Aug. 20, 2014 ... market research report is available in its catalogue: ... Medical Records http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html ... market for electronic medical records (EMR) for nearly ... comprehensive report of our findings. Our report has ...
(Date:8/20/2014)... England , August 20, 2014 ... be Conducted in the US  KalVista Pharmaceuticals ... macular edema (DME), today announces that it has begun ... novel plasma kallikrein inhibitor, KVD001, for the treatment of ... Sun of the Beetham Eye Institute, Joslin Diabetes Center; ...
(Date:8/19/2014)... KIRKLAND, Wash. , Aug. 19, 2014 ... solutions, will be exhibiting at the 2014 NPPA Summer ... The company will be showcasing its 340B software products ... leader in 340B splitting solutions, supplying over 400 customers ... a range of 340B solutions including its latest solution, ...
Breaking Medicine Technology:EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Talyst Exhibits at the NPPA Summer Conference 2
...   Unigene Laboratories, Inc. (OTCBB: UGNE), today announced ... position of Chief Financial Officer. In this newly created position, ... company,s executive leadership team and lead the strategic direction ... Mr. Moskowitz joins Unigene after spending the previous ...
... 2012 Reportlinker.com announces that a new ... catalogue: Vaccines - ... This market research report package offers ... situation, trends and future outlook for vaccines ...
Cached Medicine Technology:Unigene Appoints David Moskowitz as Chief Financial Officer 2Unigene Appoints David Moskowitz as Chief Financial Officer 3Unigene Appoints David Moskowitz as Chief Financial Officer 4Unigene Appoints David Moskowitz as Chief Financial Officer 5Vaccines - Asia 2
(Date:8/20/2014)... York, New York (PRWEB) August 20, 2014 ... with the use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) ... LLP notes that two U.S. Senators from New York ... to seek a recall of the devices. In a ... Schumer, both Democrats, also implored the agency to seriously ...
(Date:8/20/2014)... contrast to evidence that the amygdala stimulates stress ... Research Center, Emory University have found that the ... during the early development of nonhuman primates. , ... Journal of Neuroscience . , The amygdala is ... important for responses to threatening situations and learning ...
(Date:8/20/2014)... Reinberg HealthDay Reporter TUESDAY, ... that dismantles a baby,s immune system is twice as common ... million infants says. This is the first evaluation of ... condition known as severe combined immunodeficiency (SCID), or "Bubble Boy" ... this condition by the boy in the bubble, who was ...
(Date:8/20/2014)... Santa Rosa, CA (PRWEB) August 20, 2014 ... is the 12 per diode panel band perfect spectrum that ... plants are most likely to use during photosynthesis. A ... spectral bands is that they almost exclusively reside between 440-480 ... 620-680 on the red side of the spectrum. The KIND ...
(Date:8/20/2014)... 2014 Braverman Eye Center is now ... their experienced surgeons trained in PresbyLasik. The Braverman Eye ... lost or inaccurate vision. Their diligent service and adoption ... making it possible for Presbyopia patients to have better ... in people in the age group of 40 to ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2Health News:Braverman Eye Center Now Offers Multifocal PresbyLasik in Florida by Trained Surgeons 2
... for young people do not always provide the same quality ... As our population ages and requires more healthcare, hospitals need ... over 65s and implement programs to meet their distinct needs, ... St. Michael,s Hospital. The study, published in the June ...
... (HealthDay News) -- People who seek treatment in an emergency ... likely to be readmitted to the hospital as those who ... The finding suggests that emergency departments can help reduce the ... were to present the study Friday at the Society for ...
... Reinberg HealthDay Reporter , THURSDAY, June 2 ... Americans to eat healthier meals and fight the obesity ... icon called MyPlate. MyPlate replaces the U.S. Department ... but had become too complicated in ensuing years, many ...
... conserving therapy for women 70 years and older with ... opting for radioactive implants and those with estrogen positive ... an abstract being presented at the American Society of ... University Hospital researchers on Saturday, June 4. The ...
... are one step closer to helping millions of people ... or damage from treatment of diseases. The ... Oral Health and Rehabilitation, UofL School of Dentistry, and ... the salivary gland. The National Institutes of Health supported ...
... 2 (HealthDay News) -- Obesity and insulin resistance constitute a ... according to a new study that found drinking modest amounts ... condition. For their study, published online May 23 in ... people to either abstain from alcohol or drink one (women) ...
Cached Medicine News:Health News:Not all hospitals treat elderly the same 2Health News:Emergency Care May Be Key to Hospital Readmissions 2Health News:U.S. Serves Up New Nutrition Guidelines on 'MyPlate' 2Health News:U.S. Serves Up New Nutrition Guidelines on 'MyPlate' 3Health News:ASCO: Emerging trends in radiation therapy for women over 70 with early stage breast cancer 2Health News:UofL researchers uncover mechanism in saliva production 2Health News:Obesity Greater Risk for Fatty Liver Than Alcohol, Study Finds 2
... Stainless steel workbench top ... is adjustable from 25"-34". Available ... configurations. Accessories include shelves, drawers, ... Terra is an expert in ...
... metal frames ensure cleanroom ... cleanliness and chemical resistance. ... with user-friendly pnuematic controls ... Fixed footring standard. Five ...
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
Inquire...
Medicine Products: